Neuropathology of the Blood-Brain Barrier in Epilepsy: Support to the Transport Hypothesis of Pharmacoresistance

M. Koubeissi

DOI: https://doi.org/10.5698/1535-7597-13.4.169

2013-07-01

Epilepsy Currents

Abstract:Commentary Approximately one-third of individuals with epilepsy will continue to have seizures despite treatment with antiepileptic drugs (AEDs), and failure of one AED to achieve seizure control often predicts failure of subsequent AED regimens (1). Understanding the mechanisms of drug-resistance in epilepsy is of extreme importance because of potential therapeutic implications. A number of hypotheses exist regarding these mechanisms. The intrinsic severity hypothesis argues that since drug resistance is independent of the choice of AED, then it must be related to neurobiological factors that increase disease severity (2). The target hypothesis contends that drug-resistance is due to a change in the properties of the AED targets that reduces their sensitivity (3). The transporter hypothesis suggests that upregulation of multidrug transporters in the blood-brain barrier limits access of AEDs to their targets in the brain (4). This latter hypothesis is supported by observations that multidrug transporters are overexpressed in capillary endothelial tissue resected from patients with intractable epilepsy (5). Furthermore, modulation of P-glycoprotein was shown to restore sensitivity to the antiepileptic effects of phenobarbital in a rat model of temporal lobe epilepsy (6). Regarding the mechanisms of overexpression of efflux transporters, evidence exists that seizures are associated with P-glycoprotein overexpression— but there is no agreement as to whether AEDs have a direct effect (7). Problems with the existing knowledge about the role of P-glycoprotein in drug-resistance include, among others, lack of appropriate controls in the reports of P-glycoprotein overexpression in tissue resected from patients with epilepsy, Neuropathology of the Blood-Brain Barrier and Pharmaco-Resistance in Human Epilepsy.